Clinical Trial With Mesalamine 1g Suppositories

NCT ID: NCT01172444

Last Updated: 2017-03-27

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 158 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-06-30
• Study Completion Date: 2012-12-31

Brief Summary

An Investigator-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Establish Therapeutic Equivalence of 1000 mg Mesalamine Rectal Suppositories and Canasa® Rectal Suppositories (1000 mg Mesalamine, USP) in the Treatment of Mild to Moderate Ulcerative Proctitis will be conducted in 533 patient with a estimated duration of 18months.

Conditions

Proctitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Test

Sandoz Mesalamine 1 g Suppository

Group Type: EXPERIMENTAL

Mesalamine

Intervention Type: DRUG

Supporitory, Once Daily, Per Rectal for 6 Weeks

Reference

Canasa 1 g Suppository

Group Type: ACTIVE_COMPARATOR

Canasa

Intervention Type: DRUG

Suppository, Once Daily, Per Rectal for 6 Weeks

Placebo

Sandoz 1 g Placebo Suppository

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Suppository, Once Daily, Per Rectal for 6 Weeks

Interventions

Mesalamine

Supporitory, Once Daily, Per Rectal for 6 Weeks

Intervention Type: DRUG

Canasa

Suppository, Once Daily, Per Rectal for 6 Weeks

Intervention Type: DRUG

Placebo

Suppository, Once Daily, Per Rectal for 6 Weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Adults, male and female, 18 to 65 years of age 2. Active, mild to moderate UP, with disease activity not to exceed 15 cm beyond the anal verge: the upper disease boundary will be confirmed by flexible sigmoidoscopy/colonoscopy performed within 14 days of the Baseline Visit 3. Newly diagnosed or newly relapsed UP, where newly relapsed UP is defined as UP that has relapsed within less than and equal to 6 weeks prior to the Baseline Visit 4. A Disease Activity Index (DAI) score greater than or equal to 4 and less than or equal to 10 at the Baseline Visit; the DAI must include a Physician's Global Assessment (PGA) sub-score of less than or equal to 2, a rectal bleeding sub-score of greater than or equal to 1 and a mucosal appearance sub-score of greater than or equal to 1 5. Histological confirmation of UP with a Histological Disease Activity Score > or equal to 1 for the biopsy taken from the most severe area of disease during the flexible sigmoidoscopy/colonoscopy performed within 14 days of the Baseline Visit 6. For female patients of child-bearing potential, a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit; all female patients will be considered of child-bearing potential unless they are post-menopausal for at least one year or have been surgically sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) 7. Female patients of childbearing potential must be practicing one of the following methods of birth control and must agree to continue with regimen throughout the study: hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of one full cycle (based on the patient's usual menstrual cycle period) before investigational product administration; total abstinence from sexual intercourse (since the last menses before investigational product administration); intrauterine device; double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream); Male patients must also agree to use acceptable methods of birth control with their female partners, and this may include use of a male condom plus spermicide. 8. Ability to give written informed consent 9. Ability and willingness to comply with study requirements, including dosing procedures, diary completion, and study visits

Exclusion Criteria

1. Known history of allergic reaction or clinically significant intolerance to aspirin or salicylate derivatives (including mesalamine) or non-active ingredients of the investigational product 2. Onset of UP relapse >6 weeks prior to the Baseline Visit for patients experiencing a relapse of their UP (i.e., patients who are not newly diagnosed) 3. Severe UP as defined by a DAI score of greater than or equal to 11 or a PGA sub-score of 3 4. Histological Disease Activity Score > or equal to 1 for the biopsy taken from the normal tissue above the disease margin during the flexible sigmoidoscopy/colonoscopy performed within 14 days of the Baseline Visit 5. UP with disease involvement greater than 15 cm beyond the anal verge as confirmed on flexible sigmoidoscopy/colonoscopy 6. Prior unsuccessful treatment of active UP or active ulcerative colitis with rectally administered mesalamine preparations of any strength 7. Any prior treatment of UP or ulcerative colitis with any oral 5-aminosalicylic acid product if used at >2 g/day, regardless of treatment outcome 8. Use of local, rectally administered therapies for UP or ulcerative colitis (e.g., suppositories or enemas containing mesalamine, etc.) within 30 days of the Baseline Visit 9. Use of any of the following medications: - Biological therapies (e.g., infliximab) within 90 days of the Baseline Visit - Immunosuppressive/immunomodulating (e.g., azathioprine) medications within 90 days of the Baseline Visit - Oral, intravenous, intramuscular, or rectally administered corticosteroids within 30 days of the Baseline Visit; the use of intranasal and/or inhaled corticosteroids is permitted - Oral 5-aminosalicylic acid products within 7 days of the Baseline Visit, if used at & less than or equal to 2 g/day - Oral, intravenous, or intramuscular antibiotics within 7 days of the Baseline Visit - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) within 7 days of the Baseline Visit; low-dose aspirin (less than or equal to 325 mg/day) taken for cardio-protective reasons is permitted - Antidiarrheals, antispasmodics, and iron therapy within 7 days of the Baseline Visit - Transdermal nicotine products within 7 days of the Baseline Visit 10. A change in regimen (i.e., dosage or frequency of use) of permitted medications within 30 days of the Baseline Visit, or any plans to change the regimen during the course of this study 11. Use or treatment with an investigational drug, therapy, or device within 30 days of the Baseline Visit 12. A planned change in tobacco usage (e.g., smoking, oral tobacco) during the study 13. Female patients who are pregnant, planning a pregnancy, or who are breastfeeding 14. Diseases interfering with the DAI assessment, including but not limited to, hemorrhoids and anal fissures 15. History of Crohn Disease, short bowel syndrome, or bowel surgery (except appendectomy), or active peptic ulcer 16. A positive stool culture for enteric pathogens (Salmonella, Shigella, Yersinia, Campylobacter, Vibrio, E. coli O157/H7), detection of Clostridium difficile toxin through immunoassay, or enteric parasites and their ova (including Giardia, Cryptosporidium, and Entamoeba histolytica) on routine microscopy at the Screening Visit 17. Significant impairment of renal or hepatic function, as defined by any of the following: - Creatinine >1.5 x Upper Limit Normal (ULN) - Alanine Amino Transferase (ALT) >2.5 x ULN - Aspartate Amino Transferase (AST) >2.5 x ULN 18. Serologic positivity for the Hepatitis B virus (HBV), the Hepatitis C virus (HCV), the Human Immunodeficiency Virus (HIV), or Treponema pallidum (the causative agent of syphilis) 19. Known history of idiopathic / chronic pancreatitis 20. History of active drug or alcohol abuse within the past year, or physical examination findings indicating the same 21. Current clinically significant urinary tract obstruction 22. History of coagulation disorders, including those requiring treatment with anticoagulant drugs (except for aspirin taken at ≤325 mg/day for cardio-protective reasons 23. Current active malignancy or history of malignancy within the past five years, except for cervical carcinoma in situ, squamous or basal cell carcinoma of the skin that has been surgically removed, or prostate cancer that is being managed by watchful waiting (observation alone) 24. History of pelvic irradiation 25. Any other clinically significant abnormal medical condition that in the Investigators judgment would put the patient at increased risk of illness or injury, would interfere with study participation or would interfere with the evaluation or quality of the data 26. Inability or unwillingness to understand and comply with the requirements of the protocol for any reason, including dosing procedures and visit requirements 27. Previous randomization in this study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sandoz

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Kamineni Hospitals, 4-1-1227, King Koti Road, Abids

Hyderabad, Andhra Pradesh, India

Nizam's Instiute of Medical Sciences, Department of Gastroenterology

Hyderabad, Andhra Pradesh, India

Andhra Hospitals

Vijayawada, Andhra Pradesh, India

Nagarjuna Hospitals Limited

Vijayawada, Andhra Pradesh, India

Manikya Institute of Gastroenterology and Hepatology, MVV Chambers,203,204

Visakhapatnam, Andhra Pradesh, India

Institute of Digestive and Liver Diseases

Guwahati, Assam, India

Global Liver & Gastroenterology Centre, E-5/24, Opp Arera Petrol Pump

Arera Colony, Bhopal, India

Indira Gandhi Institute of Medical Sciences

Sheikhpura, Patna, Bihar, India

Department of Gastroenterology, Sheth V. S. General Hospital

Ahmedabad, Gujarat, India

Ratandeep Surgical Hospital & Endoscopy Clinic

Ahmedabad, Gujarat, India

Dr. Bhatnagar's Clinic

Ahmedabad, Gujarat, India

Apollo Hospital International Ltd.

Ahmedabad, Gujarat, India

Gastro Care Clinic

Rajkot, Gujarat, India

Gastro Care

Surat, Gujarat, India

Gokula Metropolis Clinical Research Center, M.S.Ramaiah Memorial Hospital, New BEL Road, MSRIT Post

Bangalore, Karnataka, India

PVS Memorial Hospital

Kochi, Kerala, India

Sree Gokulam Medical College and Research Foundation

Thiruvanathapuram, Kerala, India

Gut- N-Hepa Care

Indore, Madhya Pradesh, India

KEM Hospital & Research Centre, Department of Surgery

Pune, Maharashtra, India

Midas Institute of Gastroenterology

Rāmdaspeth, Nagpur, India

Department of Gastroentrology, Postgraduate Institute of Medical Education & Research

Chandigarh, Punjab, India

Dr. Nijhawan's Clinic

Jaipur, Rajasthan, India

Sharma Gastroenterology Centre

Jaipur, Rajasthan, India

Kala Endoscopy & Liver Clinic

Jodhpur, Rajasthan, India

Apollo Speciality Hospitals, Lake View Road, K. K. Nagar

Madurai, Tamil Nadu, India

Ajanta Hospital and IVF Center 765, ABC Complex , Kanpur Road

Alambagh, Lucknow, Uttar Pradesh, India

C.S.M Medical University, Department of Surgical Gastroenterology, New Surgical Block (NSB)

Lucknow, Uttar Pradesh, India

Dept. of Gastroenterology, Fortis Hospital, B-22, Sector-62

Noida, Uttar Pradesh, India

Samvedna Hospital, B 27/88G, New Colony

Ravindrapuri, Varanasi, India

Anand Multispeciality Hospitals Pvt Ltd, White house, Opp Rajasthan Hospital,Shahibaug

Ahmedabad, , India

Leads Medical Center, First Floor, Ozone Complex

Hyderabad, , India

Dept. of Gastroenterology & Hepatology, Deccan College of Medical Sciences,Owaisi Hospital & Research Centre

Hyderabad, , India

RAI Speciality Care Centre

Jaipur, , India

School of Digestive and Liver Diseases, IPGME&R

Kolkata, , India

Gastroenterology and Endoscopy Center

Nagpur, , India

Senior Consultant-Gastroenterology and Hepatology, Indraprastha Apollo Hospitals

New Delhi, , India

Krishna Institute of Medical Sciences Ltd

Secunderabad, , India

Liver Clinic

Surat, , India

Countries

India

Other Identifiers

MESA-ULP3125

Identifier Type: -

Identifier Source: org_study_id